Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to arvanil, an endocannabinoid and vanilloid hybrid, in rats

Life Sciences

Volumn 83, Issue 3-4, 2008, Pages 85-91

  Kopczyńska, Beata ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Arvanil; Cannabinoids; CB1 receptor; Rat; Regulation of blood pressure; Regulation of breathing; VR1 receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ANANDAMIDE; ARVANIL; CANNABINOID 1 RECEPTOR; CAPSAICIN; CHLORALOSE; ENDOCANNABINOID; RUTHENIUM RED; URETHAN; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING RATE; CARDIOPULMONARY FUNCTION; CONTROLLED STUDY; DIAPHRAGM MOVEMENT; DRUG EFFECT; DRUG RECEPTOR BINDING; HYBRID; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; TIDAL VOLUME;

ANILIDES; ANIMALS; BLOOD PRESSURE; CAPSAICIN; CINNAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; MORPHOLINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RESPIRATION; RESPIRATION DISORDERS; RUTHENIUM RED; TIDAL VOLUME; TRPV CATION CHANNELS;

RATTUS;

EID: 46449111357     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.04.023     Document Type: Article

References (42)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., and Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100 (2000) 685-688
2. Andersson D.A., Adner M., Högerstätt E.D., and Zygmunt P.M. Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptors agonists. Molecular Pharmacology 62 (2002) 705-713
3. Begg M., Pacher P., Bátkai S., Osei-Hyaiman D., Offertáler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacology & Therapeutics 106 (2005) 133-145
4. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60 (2001) 155-163
5. Brooks J.W., Pryce G., Bisogno T., Jaggar S.I., Hankey D.J.R., Brown P., Bridges D., Ledent C., Bifulco M., Rice A.S.C., Di Marzo V., and Baker D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. European Journal of Pharmacology 439 (2002) 83-92
6. Cabranes A., Venderova K., de Lago E., Fezza F., Sánchez A., Mestre L., Valenti M., Garcia-Merino A., Ramos J.A., Di Marzo V., and Fernández-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease 20 (2005) 207-217
7. Correll C.C., Phelps P.T., Anthes J.C., Umland S., and Greenfeder S. Cloning and pharmacological characterization of mouse TRPV1. Neuroscience Letters 370 (2004) 55-60
8. Cosenza M., Gifford A.N., Gatley S.J., Pyatt B., Liu Q., Makriyannis A., and Volkov N.D. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse 38 (2000) 477-482
9. De Lago E., Urbani P., Ramos J.A., Di Marzo V., and Fernández-Ruiz J. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Research 1050 (2005) 210-216
10. De Lago E., Gustafsson S.B., Fernández-Ruiz J., Nilsson J., Jacobsson S.O.P., and Fowler C.J. Acyl-based anandamide uptake inhibitor cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry 99 (2006) 677-688
11. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., and Di Marzo V. Overlap between the ligand recognition proprieties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. Federation of European Biochemical Societies Letters 483 (2000) 52-56
12. Di Marzo V., Breivogel C., Bisogno T., Melck D., Patrick G., Tao Q., Szallasi A., Razdan R.K., and Martin B.R. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. European Journal of Pharmacology 406 (2000) 363-374
13. Di Marzo V., Melck D., De Petrocellis L., and Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins & other Lipid Mediators 61 (2000) 43-61
14. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., and Fernández-Ruiz J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. European Journal of Pharmacology 420 (2001) 123-131
15. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K., and Martin B.R. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands. Biochemical and Biophysical Research Communications 281 (2001) 444-451
16. Di Marzo V., Griffin G., De Petrocellis L., Brandi I., Bisogno T., Williams W., Grier M.C., Kulasegram S., Mahadevam A., Razdan R.K., and Martin B.R. A structure/activity relationship study on arvanil an endocannabinoid and vanilloid hybrid. Journal of Pharmacology and Experimental therapeutics 300 (2002) 984-991
17. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglangins, Leukotienes and Essential Fatty Acids 66 (2002) 377-391
18. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice A.S., and Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Molecular Cell Neuroscience 15 (2000) 510-521
19. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiological Reviews 83 (2003) 1017-1066
20. Gu Q., Lin R.-L., Hu H.-Z., Zhu M.X., and Lee L.-Y. 2-Aminoethoxydiphenyl borate stimulates pulmonary C neurons via the activation of TRPV channels. American Journal of Physiology 288 (2005) L932-L941
21. Hiley C.R., and Ford W.R. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signaling. Biological Reviews of the Cambridge Philosophical Society 79 (2004) 187-205
22. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., and Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 and CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America 96 24 (1999) 14136-14141
23. Kopczyńska B. The contribution of VR1 and CB1 receptors and the role of the afferent vagal pathway in modeling of cardio-respiratory effects of anandamide in rats. Life sciences 80 (2007) 1738-1745
24. Kopczyńska B., and Szereda-Przestaszewska M. Apnoeic responses to pulmonary and systemic challenge of capsaicin in cats. Journal of Physiology and Pharmacology 49 1 (1998) 25-35
25. Kopczyńska B., and Szereda-Przestaszewska M. Supranodose vagotomy eliminates anandamide-evoked cardiorespiratory depression in anaesthetized rats. Respiratory Physiology & Neurobiology 152 (2006) 143-151
26. Kwolek G., Zakrzeska A., Schlicker E., Göthert M., Godlewski G., and Malinowska B. Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. British Journal of Pharmacology 145 (2005) 567-575
27. 1-like cannabinoid receptors. The Journal of Pharmacology and Experimental Therapeutics 281 (1997) 1030-1037
28. Lin Y.S., and Lee L.-Y. Stimulation of pulmonary vagal C-fibers by anandamide in anaesthetized rats: role of vanilloid type 1 receptors. Journal of Physiology 539.3 (2002) 947-955
29. Lo Y.-K., Chiang H.-T., and Wu S.-N. Effect of arvanil (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide-capsaicin hybrid, on ion currents in NG108-15 neuronal cells. Biochemical Pharmacology 65 (2003) 581-591
30. Malinowska B., Kwolek G., and Gothert M. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn-Schmiedeberg's Archiv Pharmacology 364 (2001) 562-569
31. Martin B.R. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sciences 77 14 (2005) 1543-1558
32. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., and Di Marzo V. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochemical and Biophysical Research Communications 262 (1999) 275-284
33. McQueen D.S., Bond S.M., Smith P.J.W., Balali-Mood K., and Smart D. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandmide in anaesthetized rats. European Journal of Pharmacology 491 (2004) 181-189
34. Pacher P., Bátkai S., and Kunos G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. Journal of Physiology 558.2 (2004) 647-657
35. 1 cannabinoid receptors. Life Sciences 65 (1999) 597-605
36. Piomelli D., Giuffrida A., Calignano A., and Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences 21 (2000) 218-224
37. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., and Perwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. British Journal of Pharmacology 132 (2001) 631-640
38. Schmid K., Niederhoffer N., and Szabo B. Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Archiv Pharmacology 368 (2003) 301-308
39. Smith P.J.W., and McQueen D.S. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. British Journal of Pharmacology 134 (2001) 655-663
40. Szereda-Przestaszewska M., and Wypych B. Laryngeal constriction produced by capsaicin in the cat. Journal of Physiology and Pharmacology 47 (1996) 351-360
41. 1 cannabinoid receptor in the hypotensive action of anandamide. European Journal of Pharmacology 278 (1995) 279-283
42. Varga A., Németh J., Szabó A., McDougall J.J., Zhang C., Elekes K., Pintér E., Szolcsányi J., and Helyes Z. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neuroscience Letters 385 (2005) 137-142